Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...
A randomized trial showed that a smartphone-delivered digital CBT intervention improved generalized anxiety disorder symptoms in adults. The self-paced program uses evidence-based CBT techniques such ...
The science of self-worth, the power of neuroplasticity, and 10 practical steps to help you uproot old patterns and embrace ...
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), today announced that the U.S. Food and Drug Administration (FDA) has ...
If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...
The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...
The drug, CUTX-101, is intended for the treatment of Menkes disease, a rare X-linked recessive genetic disorder affecting ...
Sentynl Therapeutics, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, have announced that the U.S. Food and Drug Administration (FDA) has accepted ...
FMS: the Future of Memory and Storage, the industry's premier event for next-generation memory and storage, and the world's largest independent memory and storage conference, today announced that its ...
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- ...
Accuray Incorporated today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan. This phase is designed to realign its organization to produce ...
ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as ...